Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/66885
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMarathe, C.en
dc.contributor.authorRayner, C.en
dc.contributor.authorJones, K.en
dc.contributor.authorHorowitz, M.en
dc.date.issued2011en
dc.identifier.citationExperimental Diabetes Research, 2011; 2011:279530-1-279530-10en
dc.identifier.issn1687-5214en
dc.identifier.issn1687-5303en
dc.identifier.urihttp://hdl.handle.net/2440/66885-
dc.description.abstractGlucagon-like peptide 1 (GLP-1) is a hormone secreted predominantly by the distal small intestine and colon and released in response to enteral nutrient exposure. GLP-1-based therapies are now used widely in the management of type 2 diabetes and have the potential to be effective antiobesity agents. Although widely known as an incretin hormone, there is a growing body of evidence that GLP-1 also acts as an enterogastrone, with profound effects on the gastrointestinal motor system. Moreover, the effects of GLP-1 on gastrointestinal motility appear to be pivotal to its effect of reducing postprandial glycaemic excursions and may, potentially, represent the dominant mechanism. This review summarizes current knowledge of the enterogastrone properties of GLP-1, focusing on its effects on gut motility at physiological and pharmacological concentrations, and the motor actions of incretin-based therapies. While of potential importance, the inhibitory action of GLP-1 on gastric acid secretion is beyond the scope of this paper.en
dc.description.statementofresponsibilityChinmay S. Marathe, Christopher K. Rayner, Karen L. Jones, and Michael Horowitzen
dc.language.isoenen
dc.publisherHindawi Publishing Corporationen
dc.rightsCopyright © 2011 Chinmay S. Marathe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.subjectGastrointestinal Tract; Animals; Humans; Diabetes Mellitus, Type 2; Gastrointestinal Hormones; Peptides; Gastrointestinal Motility; Movement; Glucagon-Like Peptide 1; Incretinsen
dc.titleEffects of GLP-1 and incretin-based therapies on gastrointestinal motor functionen
dc.typeJournal articleen
dc.identifier.rmid0020112359en
dc.identifier.doi10.1155/2011/279530en
dc.identifier.pubid27959-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidRayner, C. [0000-0002-5527-256X]en
dc.identifier.orcidJones, K. [0000-0002-1155-5816]en
dc.identifier.orcidHorowitz, M. [0000-0002-0942-0306]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_66885.pdfPublished version1.76 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.